Research programme: antibacterials - Spero Therapeutics/Roche

Drug Profile

Research programme: antibacterials - Spero Therapeutics/Roche

Alternative Names: Multiple virulence factor Regulator inhibitors - Spero; MvfR inhibitors - Spero; MvfR programme - Spero

Latest Information Update: 28 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Spero Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pseudomonal infections
  • No development reported Gram-negative infections

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Gram-negative-infections(Treatment-resistant) in USA
  • 25 Apr 2017 Pharmacodynamic results from a preclinical study in Pseudomonal infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 15 Dec 2015 Spero Therapeutics and Evotec AG agree to co-develop antibacterials for Gram-negative infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top